ImmunoVaccine (IMV) has notable insider buying

ImmunoVaccine (T:IMV)

Pierre Labbé, a Senior Officer, acquired 20,800 Common Shares on a direct ownership basis at a price of $1.890 through the public market on February 12th, 2018. This represents a $39,312 investment into the company's shares and an account share holdings change of 7.6%.

Frederic Ors, CEO and Director, acquired 16,000 Common Shares on a direct ownership basis at a price of $1.884 through the public market on February 13th, 2018. This represents a $30,146 investment into the company's shares and an account share holdings change of 5.2%.

Immunovaccine Inc is a Canada-based clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.